Having discovered that SQ administration of neurotrophins may not lead to clinical success in a CNS disease, the next neurotrophin to enter clinical trials, glial-derived neurotrophic factor (GDNF), was administered by ICV injection for the treatment of PD [107]. The gene discussed is GDNF; the disease is Parkinson disease.